Author Correction: Phase 3 STOP-HS1 and STOP-HS2 Trials of Povorcitinib for Hidradenitis Suppurativa: Randomized, Double-Blind, Placebo-Controlled Studies

Category	Detail
Condition	Clinical topic addressed by the source article: Author Correction
Key Mechanisms	Not addressed in the correction.
Target Population	Patients or participants described in the source article.
Care Setting	Correction to the published STOP-HS1 and STOP-HS2 trial article and supplementary materials.

The corrected mean (range) baseline disease duration for recalcitrant, longstanding HS is 9.7 (0.4–49.1)–10.8 (0.4–57.7) years.
In STOP-HS2, three patients stopped treatment after week 12: two by physician decision and one by withdrawal.
One patient withdrew after completing treatment through week 12, replacing the prior report that two patients discontinued then and both withdrew.
The STOP-HS1 75 mg entries for ≥3-point decrease in Skin Pain NRS and Skin Pain NRS30 should carry superscript f with their P values, not e.
Extended Data Fig. 5e, f should show a blue rather than grey dotted line between weeks 18 and 24, and numerical values adjacent to week 6 dots should be placed beside the week 12 dots.
Supplementary Table 6A’s Week 12 values in the “A75, Baseline A count, 3–5” section are corrected to 36.8 (25/68), 35.3 (18/51), 37.2 (16/43).

The correction concerns participants in the STOP-HS1 and STOP-HS2 trials; it does not provide prescribing guidance.

The correction clarifies trial discontinuation reporting and selected efficacy-table and figure data; it does not change treatment recommendations.

Clinical Scorecard: Author Correction: Phase 3 STOP-HS1 and STOP-HS2 Trials of Povorcitinib for Hidradenitis Suppurativa